Like other retinal disease therapy markets, the retinal vein occlusion (RVO) with macular edema (ME) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug used off-label for RVO with ME, despite the availability of two effective approved therapies—Genentech’s Lucentis and Regeneron’s Eylea. These therapies, all of which target vascular endothelial growth factor (VEGF) and have been shown to improve visual acuity in RVO with ME patients, compete directly for patient share. The intravitreal corticosteroid implant Ozurdex, also approved for RVO with ME, is an alternative option. As the RVO with ME pipeline becomes more active, it is essential to understand where the current players fit in the RVO with ME treatment algorithm.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed RVO with ME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed RVO with ME patients?
  • How have each of the VEGF inhibitors (Avastin, Eylea, and Lucentis) been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of RVO with ME patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of RVO with ME patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Avastin, Eylea, Lucentis, Ozurdex, triamcinolone, Triesence

Key analysis provided:

  • Brand / therapy usage across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms Retinal Vein Occlusion with Macular Edema US January 2020

Author(s): Thomas Cronin, Ph.D

Since joining DRG in late 2019, Tom has worked on reports focusing on psychiatric and ophthalmologic disorders for the CNS ; His background is in biochemistry and he previously worked in the intellectual property field as a registered Patent Agent. Prior to joining DRG, Tom was an Intellectual Property Manager in a Boston-based biopharmaceutical company focusing on treating metabolic diseases and disorders. He has also worked for several internationally recognized law firms representing corporate and institutional clients in all matters of life science – related intellectual property.


Related Reports

Retinal Vein Occlusion | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion...

View Details

Retinal Vein Occlusion | Executive Insights | Executive Insights (US)

Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are...

View Details